Congressional staff deposed Valeant CEO J. Michael Pearson last week in advance of a public hearing before the Senate Special Committee on Aging scheduled for April 27.
Lawyers from both the majority and minority staff conducted the deposition; however, no committee members were in attendance.
Senate Special Committee on Aging Chairwoman Susan Collins (R-Maine) and Ranking Member Claire McCaskill (D-Mo.) sought the deposition after Pearson failed to comply with a subpoena and appear before the panel April 8. For months, Valeant has received intense public scrutiny for allegedly increasing the prices of Isuprel and Nitropress by 525 percent and 212 percent, respectively.